Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

BioStock: Deal gives Iconovo long-term revenue potential

In July, Iconovo announced it had signed a regional licensing agreement with BNC Korea for the development of two inhalation capsule formulations for ICOcap: the generic forms of Novartis’s Ultibro and Seebri. The territory covered by BNC Korea represents about 15 per cent of total sales of the two formulations, giving Iconovo a substantial business opportunity.Read the full article at biostock.se: https://www.biostock.se/en/deal_gives_iconovo_long-term_revenue_potential/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se 

European Lingerie Group AB announces approval of annual report 2019

On 20 July 2020 European Lingerie Group AB (the "Company" and together with its subsidiaries from time to time, the “Group”) announced that the expected date of delivery of its annual audited financial statements for the year 2019 would be 17 August 2020.The Group hereby announces that on 17 August 2020 it has duly approved and signed its annual audited financial statements for the year 2019 and those will be published on the Group’s website no later than on 27 August 2020. This information is information that European Lingerie Group AB (publ) is obliged to make public pursuant to the EU

More than 50% of patients enrolled in Follicum's Phase II study of FOL-005 for stimulation of hair growth

Follicum AB ("Follicum" or the "company") today announced that more than 50% of the patients have  been recruited in the ongoing, clinical phase IIa study with FOL-005. The study involves 200 male patients with hair loss who are treated daily for four months with a newly developed topical formulation of FOL-005 or placebo. The study is being conducted at the Clinical Research Center for Hair and Skin Science ("CRC") in Berlin, at proDERM in Hamburg and at CentroDerm® in Wuppertal.Two previous clinical studies have shown that intradermal injections of FOL-005 are an effective and safe

Valor Global FX Fund reports NAV rate for July

Valor Global FX, FX International AB (publ.) fund in Malta reports that the NAV rate, as expected, initially continued down with approximately -2.62% during July. However, trades show positive figures and the reason for the loss is fees and exchange rates.Valor Global FX has, as expected, continued with an initial period that is negative and is down by about -2.62% during July.  This is due to initial and running costs and exchange cost from Euro to SEK as the Swedish krona value changed quite a lot during the period. In July, trade gave a surplus of just over 4 kEUR. We want to get

Yilmaz Mahshid takes office as CEO of Medivir on 14 September

Stockholm — Medivir AB (Nasdaq Stockholm: MVIR) announced today that Dr. Yilmaz Mahshid will assume his position as CEO on September 14, 2020. Uli Hacksell, who has been CEO since October 2018, will remain as a Board Member of Medivir. Yilmaz Mahshid joins Medivir from his recent position as CFO at PledPharma. He was prior to that Investment Manager at Industrifonden. He has also worked as a health care analyst at Pareto Securities and at Öhman Fondkommission. Yilmaz holds a doctorate from the Department of Medical Biochemistry and Biophysics at Karolinska Institute. He began his career

NOTE initiates collaboration with BrainLit

The Swedish company BrainLit is a world leader in biocentric light. The company delivers healthy environments by recreating daylight and generating personalised light indoors. Prior to the launch of its new innovative health system, BrainLit has chosen to collaborate with NOTE. The deal is expected to have great potential and in the near future reach a turnover of at least SEK 50 million per year. Production will take place at NOTE's plant in Lund. During the autumn, BrainLit will launch a completely unique health system on the market, which on a personal level reflects natural daylight

Bioservo Technologies AB Interim Report January - June 2020

Second quarter in figures · Net sales SEK 4.8 M (3.5) · EBITDA of SEK -3.8 M (-4.8)  · EBIT of SEK -4.8 M (-5.8) · Earnings for the period was SEK -4.8 M (-5.8) · Earnings per share before and after dilution amounted to SEK -0.34 (-0.65) · Cash flow from operating activities for the period amounted to SEK -6.0 M (-7.4) · At 30 June, cash and cash equivalents were SEK 44.2 M (9.9)  First half-year in figures · Net sales SEK 7.8 M (5.2) · EBITDA of SEK -10.4 M (-9.3) · EBIT of SEK -12.4 M (-11.1) · Earnings for the period was SEK -12,4 M (-11.1)  ·

ExpreS2ion appoints new CFO

Hørsholm, Denmark, August 18, 2020 – ExpreS2ion Biotech Holding AB (“ExpreS2ion” or the “Company”) hereby announces that it has appointed Mr. Keith Alexander as new Chief Financial Officer (CFO). Mr. Alexander brings more than 20 years of corporate banking and strategy consulting experience and will initially be focused on strengthening the Company’s financial strategies and investor relations function. Mr. Alexander will begin his employment on October 1, 2020 and be based out of ExpreS2ion’s headquarters in Hørsholm, Denmark. The appointment of Mr. Alexander follows the strategy

Interim report, January–June 2020

Strengthened balance sheet in a challenging environmentJanuary–June 2020 · Revenue amounted to TSEK 94,559 (109,348). · Operating profit amounted to TSEK -11,958 (-4,389). · Operating profit excluding non-recurring costs amounted to TSEK -11,958 (7,908). · Profit after tax amounted to TSEK -18,186 (8,418). · Earnings per share amounted to -0.51 SEK (0.29). April-June 2020 · Revenue amounted to TSEK 34,983 (55,987). · Operating profit amounted to TSEK -17,313 (-9,049). · Operating profit excluding non-recurring costs amounted to TSEK -17,313 (3,248). ·

Olvi Group's Harf-Year Report, 1 January to 30 June 2020 (6 months)

OLVI PLC                             Half-Year Report 18.8.2020 at 9:00 am   OLVI GROUP’S HALF-YEAR REPORT, 1 JANUARY TO 30 JUNE 2020 (6 MONTHS) Half-year report in brief Olvi Group’s sales volume, net sales and operating profit improved during the review period. Thanks to a strong market position, sales volume and operating profit increased also in the second quarter despite the impacts of the corona pandemic. The financial standing and cash at hand remain at the previous year’s good level. Reinstating the earnings guidance The corona pandemic caused a sudden change in

Nordic Mining ASA (OAX:NOM) - Interim report per 30 June 2020

Enclosed please find Nordic Mining’s interim report and company presentation for the second quarter of 2020. The interim report and company updates will be presented digitally today, Tuesday 18 August 2020 at 10.00 (CET). The presentation and Q&A session will be held in English and transferred via webcast at: https://channel.royalcast.com/webcast/hegnarmedia/20200818_7/ You will have the opportunity to post questions online throughout the webcast session.Important events in the second quarter of 2020 and year to date: CORPORATE Adequately financed well into 2021 In January 2020,

TOPCAB strengthens its presence in Nacka and Värmdö

Cabonline Group has connected about twenty cars from Värmdötaxi and grows hereby in the south eastern archipelago area of Stockholm.The transporters who previously belonged to Värmdötaxi will as of this week drive under the brand TOPCAB. With these new drivers TOPCAB increase its presence in the Stockholm region. - This means that we create a new market for TOPCAB in Nacka and Värmdö, and that travellers can continue to ride with highly appreciated transporters and drivers, says Magnus Klintbäck, CEO Cabonline Stockholm. All drivers are now undergoing training to ensure the same high

Azelio signs agreement with ALEC Energy to set up renewable energy storage site in Masdar City

Azelio will install a verification project in Abu Dhabi in Q3 2020 together with Masdar and Khalifa University. The purpose of the installation is to evaluate Azelio’s energy storage technology for inclusion in the Masdar product portfolio for current and future renewable energy projects. An agreement has now been signed with ALEC Energy to set up the Azelio project site in Masdar city, Abu Dhabi.The preparation for Azelio’s energy storage installation in Abu Dhabi is progressing according to plan. The project has reached an important milestone in a signed agreement with ALEC Energy to

ExpreS2ion provides update on anticipated development of the breast cancer vaccine candidate AV001, including a probable change in its ownership stake in AdaptVac

Hørsholm, Denmark, August 18, 2020 – ExpreS2ion Biotech Holding AB (“ExpreS2ion” or the “Company”) hereby announces that ExpreS2ion wishes to exercise the option to inlicense AV001 before it expires on February 26, 2021. The exercise of the option is subject to the Company obtaining the necessary financing to fund the exercise of the option and the further preclinical development of AV001. If so, the Company expects to be able to submit an application to start clinical trials in the first half of 2022. The Company furthermore announces that it will transfer 16 percent of its joint venture

Imfinzi granted FDA Priority Review for less-frequent, fixed-dose use

18 August 2020 07:00 BST Imfinzi granted FDA Priority Review for less-frequent, fixed-dose use Option would extend dosing to four weeks in non-small cell lungand bladder cancer reducing medical visits by half AstraZeneca's Imfinzi (durvalumab) has received acceptance for its supplemental Biologics License Application (sBLA) and has also been granted Priority Review in the US for a new four-week, fixed-dose regimen for treatment in the approved indications of non-small cell lung cancer (NSCLC) and bladder cancer. If approved, Imfinzi could be administered intravenously every

Unique temples near Bangkok offer out-of-the-ordinary experiences

Temple visits are a highlight of any trip to Thailand.Temple visits are a highlight of any trip to Thailand. The ornate pagodas and golden Buddha images make temples must-see attractions with many options for visitors to choose from. There are several thousand temples dotted around Bangkok alone, making it easy to simply temple-hop in the capital city. But in a country with so many beautiful temples, it’s worth it to venture a little farther afield.Here, we invite visitors to take a step inside some of the most unique temples near Bangkok for an out-of-the-ordinary experience in off-the-

KONE to equip phase two of Chongqing Metro Line 6 in China

KONE Corporation, press release, August 18, 2020  KONE Corporation, a global leader in the elevator and escalator industry, will deliver 83 escalators and 20 elevators to the second phase of the Metro Line 6 in Chongqing, in southwest China.The Line 6 will become an important connection running through the Liangjiang New Area in the north of the city. The Liangjiang New Area and especially its Yuelai district are important hubs bringing together international business, exhibitions and conferences, leisure tourism, cultural creativity, and ecological living. The new metro

Nevisense selected for ‘SpotCheck’ remote melanoma detection evaluation study by The Ronald O. Perelman Department of Dermatology at NYU Langone Health

Stockholm, Sweden and New York, USA - August 18, 2020 - SciBase Holding AB  ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that Nevisense will be included in a large clinical study initiated by The Ronald O. Perelman Department of Dermatology clinic at NYU Langone Health.  The SpotCheck study will investigate the use of Nevisense as a point-of-care diagnostic tool to assist with skin cancer detection in a remote setting such as a non-specialist practice or pharmacy. The study will

IMPACT COATINGS AB (PUBL), INTERIM REPORT APRIL-JUNE 2020

FINANCIAL RESULTS SECOND QUARTER 2020 · Net revenue amounted to SEK 5,016 thousand (22,560) · Total income amounted to SEK 9,726 thousand (17,452) · Operating profit amounted to SEK -6,305 thousand (-4,185) · Operating profit after financial items amounted to SEK -6,305 thousand (-4,191) · Cash flow amounted to SEK -2,299 thousand (-12,413) · Equity-to-assets ratio amounted to 282% (130) · Coating system order backlog at period end amounted to EUR 3,765 thousand (2,084) FINANCIAL RESULTS JANUARY-JUNE 2020 · Net revenue amounted to SEK 10,039 thousand (25,507)

Interim report for the period January 1 - June 30, 2020

During the quarter, Climeon made further progress within geothermal, despite the on-going pandemic. Two new power plants have been commissioned in Japan and the first geothermal order was received in Taiwan. Order intake increased by 67 percent and amounted to SEK 40.9 million. Despite the challenging market situation, Climeon had a positive cash flow from operating activities during the quarter. Total cash and cash equivalents and short-term investments increased by 5 percent and amounted to SEK 100.6 million at the end of the period. April - june · Order intake amounted to SEK 40.

Starbreeze AB (publ) Interim Half-Year Q2 2020 report

Second quarter 2020 · Net sales were SEK 31.3 million (160.0). PAYDAY accounted for SEK 28.1 million (14.4). · EBITDA* amounted to SEK 15.5 million (-25.8). · Amortization and depreciation totalled SEK 10.5 million (22.0). · Costs related to the reconstruction were SEK 3.8 million (12.6). · Loss before tax of SEK -2.2 million (-60.1). · Basic and diluted earnings per share were SEK -0.01 (-0.20). · The summer sale run by digital distribution platform Steam had positive impact on sales during the quarter. First half 2020 · Net sales were SEK 53.3 million (207.8)

Lipidor publishes interim report for H1 2020

Today, Lipidor AB publishes its interim report for the period January - June 2020. The quarterly report is available on the company's website lipidor.se  and in the attached pdf.Summary of the interim report – second quarter 2020 Lipidor has continuous positive ongoing out-licensing discussions with potential licensees. Preperations for initiation of the phase lll-study in AKP02 continues according to plan. The planned study is fully financed from existing funds. The subsidiary Emollivet AB, operational within Animal-

Traumakine Update

Faron Pharmaceuticals Oy (“Faron” or the “Company”)· €2.5 million loan guarantee from Finnvera to further expand IV IFN beta-1a manufacturing process · AGC Biologics selected as new commercial scale manufacturer · COVID-19 trials continue to investigate Traumakine treatment Company announcement, 18 August 2020 at 9.00 AM (EET)Insider information TURKU – FINLAND – Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, today provides an update on manufacturing plans for Traumakine, its investigational intravenous (IV)

There are no items matching the current filter
There are no more items matching the current filter
Back to top